.png)
Pneumococcal Vaccine Polyvalent Market by Type - Global Industry Analysis & Forecast to 2027
Published On : September 2019 Pages : 150 Category: Pharma & Healthcare Report Code : HC095426
SEGMENTS & REGIONS:
- Regions: North America, Europe, Asia- Pacific, Latin America, Middle East & Africa
Pneumococcal Vaccine Polyvalent Market by Type (Prevnar 13, Pneumovax23) - Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
The pneumococcal vaccine polyvalent market has encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period. Pneumococcal polyvalent vaccine is a functioning vaccinating operator used to anticipate infection by pneumococcal microorganisms.
Drivers and Restraints
Top-down and bottom-up approaches are used to validate the global pneumococcal vaccine polyvalent market size market and estimate the market size for company, regions segments, type segments and applications (end users). In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
Regional Insights
The data for 2021 is an estimate, based on the history data and the integrated view of industry experts, manufacturers, distributors and end users etc.
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
- Merck & Co.
- Pfizer
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
o Pneumococcal Vaccine Polyvalent Market, By Type, Estimates and Forecast, 2017-2027 ($Million)
o Prevnar 13
o Pneumovax23
o Pneumococcal Vaccine Polyvalent Market, By Key Players, Estimates and Forecast, 2017-2027 ($Million)
o Merck & Co.
o Pfizer
o Pneumococcal Vaccine Polyvalent Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Pneumococcal Vaccine Polyvalent Market, By Country
o U.S. Pneumococcal Vaccine Polyvalent Market
o Canada Pneumococcal Vaccine Polyvalent Market
o Mexico Pneumococcal Vaccine Polyvalent Market
o Europe
§ Europe Pneumococcal Vaccine Polyvalent Market, By Country
o Germany Pneumococcal Vaccine Polyvalent Market
o UK Pneumococcal Vaccine Polyvalent Market
o France Pneumococcal Vaccine Polyvalent Market
o Russia Pneumococcal Vaccine Polyvalent Market
o Italy Pneumococcal Vaccine Polyvalent Market
o Rest of Europe Pneumococcal Vaccine Polyvalent Market
o Asia-Pacific
§ Asia-Pacific Pneumococcal Vaccine Polyvalent Market, By Country
o China Pneumococcal Vaccine Polyvalent Market
o Japan Pneumococcal Vaccine Polyvalent Market
o South Korea Pneumococcal Vaccine Polyvalent Market
o India Pneumococcal Vaccine Polyvalent Market
o Southeast Asia Pneumococcal Vaccine Polyvalent Market
o Rest of Asia-Pacific Pneumococcal Vaccine Polyvalent Market
o South America
§ South America Pneumococcal Vaccine Polyvalent Market, By Country
o Brazil Pneumococcal Vaccine Polyvalent Market
o Argentina Pneumococcal Vaccine Polyvalent Market
o Columbia Pneumococcal Vaccine Polyvalent Market
o Rest of South America Pneumococcal Vaccine Polyvalent Market
o Middle East and Africa
§ Middle East and Africa Pneumococcal Vaccine Polyvalent Market, By Country
o Saudi Arabia Pneumococcal Vaccine Polyvalent Market
o UAE Pneumococcal Vaccine Polyvalent Market
o Egypt Pneumococcal Vaccine Polyvalent Market
o Nigeria Pneumococcal Vaccine Polyvalent Market
o South Africa Pneumococcal Vaccine Polyvalent Market
o Rest of MEA Pneumococcal Vaccine Polyvalent Market
Table of Contents:
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Pneumococcal Vaccine Polyvalent Market, By Type
5.1. Introduction
5.2. Global Pneumococcal Vaccine Polyvalent Revenue and Market Share by Type (2017-2027)
5.2.1. Global Pneumococcal Vaccine Polyvalent Revenue and Revenue Share by Type (2017-2027)
5.3. Prevnar 13
5.3.1. Global Prevnar 13 Revenue and Growth Rate (2017-2027)
5.4. Pneumovax23
5.4.1. Global Pneumovax23 Revenue and Growth Rate (2017-2027)
6. Pneumococcal Vaccine Polyvalent Market, By Region
6.1. Introduction
6.2. Global Pneumococcal Vaccine Polyvalent Revenue and Market Share by Regions
6.2.1. Global Pneumococcal Vaccine Polyvalent Revenue by Regions (2017-2027)
6.3. North America Pneumococcal Vaccine Polyvalent by Countries
6.3.1. North America Pneumococcal Vaccine Polyvalent Revenue and Growth Rate (2017-2027)
6.3.2. North America Pneumococcal Vaccine Polyvalent Revenue (Million USD) by Countries (2017-2027)
6.3.3. United States
6.3.3.1. United States Pneumococcal Vaccine Polyvalent Revenue (Millions USD) and Growth Rate (2017-2027)
6.3.4. Canada
6.3.4.1. Canada Pneumococcal Vaccine Polyvalent Revenue (Millions USD) and Growth Rate (2017-2027)
6.3.5. Mexico
6.3.5.1. Mexico Pneumococcal Vaccine Polyvalent Revenue (Millions USD) and Growth Rate (2017-2027)
6.4. Europe Pneumococcal Vaccine Polyvalent by Countries
6.4.1. Europe Pneumococcal Vaccine Polyvalent Revenue and Growth Rate (2017-2027)
6.4.2. Europe Pneumococcal Vaccine Polyvalent Revenue (Million USD) by Countries (2017-2027)
6.4.3. Germany
6.4.3.1. Germany Pneumococcal Vaccine Polyvalent Revenue (Millions USD) and Growth Rate (2017-2027)
6.4.4. France
6.4.4.1. France Pneumococcal Vaccine Polyvalent Revenue (Millions USD) and Growth Rate (2017-2027)
6.4.5. UK
6.4.5.1. UK Pneumococcal Vaccine Polyvalent Revenue (Millions USD) and Growth Rate (2017-2027)
6.4.6. Russia
6.4.6.1. Russia Pneumococcal Vaccine Polyvalent Revenue (Millions USD) and Growth Rate (2017-2027)
6.4.7. Italy
6.4.7.1. Italy Pneumococcal Vaccine Polyvalent Revenue (Millions USD) and Growth Rate (2017-2027)
6.4.8. Rest of Europe
6.4.8.1. Rest of Europe Pneumococcal Vaccine Polyvalent Revenue (Millions USD) and Growth Rate (2017-2027)
6.5. Asia-Pacific Pneumococcal Vaccine Polyvalent by Countries
6.5.1. Asia-Pacific Pneumococcal Vaccine Polyvalent Revenue and Growth Rate (2017-2027)
6.5.2. Asia-Pacific Pneumococcal Vaccine Polyvalent Revenue (Million USD) by Countries (2017-2027)
6.5.3. China
6.5.3.1. China Pneumococcal Vaccine Polyvalent Revenue (Millions USD) and Growth Rate (2017-2027)
6.5.4. Japan
6.5.4.1. Japan Pneumococcal Vaccine Polyvalent Revenue (Millions USD) and Growth Rate (2017-2027)
6.5.5. Korea
6.5.5.1. Korea Pneumococcal Vaccine Polyvalent Revenue (Millions USD) and Growth Rate (2017-2027)
6.5.6. India
6.5.6.1. India Pneumococcal Vaccine Polyvalent Revenue (Millions USD) and Growth Rate (2017-2027)
6.5.7. Southeast Asia
6.5.7.1. Southeast Asia Pneumococcal Vaccine Polyvalent Revenue (Millions USD) and Growth Rate (2017-2027)
6.5.8. Rest of Asia-Pacific
6.5.8.1. Rest of Asia-Pacific Pneumococcal Vaccine Polyvalent Revenue (Millions USD) and Growth Rate (2017-2027)
6.6. South America Pneumococcal Vaccine Polyvalent by Countries
6.6.1. South America Pneumococcal Vaccine Polyvalent Revenue and Growth Rate (2017-2027)
6.6.2. South America Pneumococcal Vaccine Polyvalent Revenue (Million USD) by Countries (2017-2027)
6.6.3. Brazil
6.6.3.1. Brazil Pneumococcal Vaccine Polyvalent Revenue (Millions USD) and Growth Rate (2017-2027)
6.6.4. Argentina
6.6.4.1. Argentina Pneumococcal Vaccine Polyvalent Revenue (Millions USD) and Growth Rate (2017-2027)
6.6.5. Columbia
6.6.5.1. Columbia Pneumococcal Vaccine Polyvalent Revenue (Millions USD) and Growth Rate (2017-2027)
6.6.6. Rest of South America
6.6.6.1. Rest of South America Pneumococcal Vaccine Polyvalent Revenue (Millions USD) and Growth Rate (2017-2027)
6.7. Middle East and Africa Pneumococcal Vaccine Polyvalent by Countries
6.7.1. Middle East and Africa Pneumococcal Vaccine Polyvalent Revenue and Growth Rate (2017-2027)
6.7.2. Middle East and Africa Pneumococcal Vaccine Polyvalent Revenue (Million USD) by Countries (2017-2027)
6.7.3. Saudi Arabia
6.7.3.1. Saudi Arabia Pneumococcal Vaccine Polyvalent Revenue (Millions USD) and Growth Rate (2017-2027)
6.7.4. United Arab Emirates
6.7.4.1. United Arab Emirates Pneumococcal Vaccine Polyvalent Revenue (Millions USD) and Growth Rate (2017-2027)
6.7.5. Egypt
6.7.5.1. Egypt Pneumococcal Vaccine Polyvalent Revenue (Millions USD) and Growth Rate (2017-2027)
6.7.6. Nigeria
6.7.6.1. Nigeria Pneumococcal Vaccine Polyvalent Revenue (Millions USD) and Growth Rate (2017-2027)
6.7.7. South Africa
6.7.7.1. South Africa Pneumococcal Vaccine Polyvalent Revenue (Millions USD) and Growth Rate (2017-2027)
6.7.8. Turkey
6.7.8.1. Turkey Pneumococcal Vaccine Polyvalent Revenue (Millions USD) and Growth Rate (2017-2027)
6.7.9. Rest of Middle East and Africa
6.7.9.1. Rest of Middle East and Africa Pneumococcal Vaccine Polyvalent Revenue (Millions USD) and Growth Rate (2017-2027)
7. Company Profiles
7.1. Merck & Co.
7.1.1. Business Overview
7.1.2. Service Portfolio
7.1.3. Strategic Developments
7.1.4. Financial Overview
7.2. Pfizer
7.2.1. Business Overview
7.2.2. Service Portfolio
7.2.3. Strategic Developments
7.2.4. Financial Overview
8. Pneumococcal Vaccine Polyvalent Market Forecast (2017-2027)
8.1. Global Pneumococcal Vaccine Polyvalent Revenue (Millions USD) and Growth Rate (2017-2027)
8.2. Pneumococcal Vaccine Polyvalent Market Forecast by Regions (2017-2027)
8.2.1. North America Pneumococcal Vaccine Polyvalent Market Forecast (2017-2027)
8.2.1.1. United States Pneumococcal Vaccine Polyvalent Market Forecast (2017-2027)
8.2.1.2. Canada Pneumococcal Vaccine Polyvalent Market Forecast (2017-2027)
8.2.1.3. Mexico Pneumococcal Vaccine Polyvalent Market Forecast (2017-2027)
8.2.2. Europe Pneumococcal Vaccine Polyvalent Market Forecast (2017-2027)
8.2.2.1. Germany Pneumococcal Vaccine Polyvalent Market Forecast (2017-2027)
8.2.2.2. France Pneumococcal Vaccine Polyvalent Market Forecast (2017-2027)
8.2.2.3. UK Pneumococcal Vaccine Polyvalent Market Forecast (2017-2027)
8.2.2.4. Russia Pneumococcal Vaccine Polyvalent Market Forecast (2017-2027)
8.2.2.5. Italy Pneumococcal Vaccine Polyvalent Market Forecast (2017-2027)
8.2.2.6. Rest of Europe Pneumococcal Vaccine Polyvalent Market Forecast (2017-2027)
8.2.3. Asia-Pacific Pneumococcal Vaccine Polyvalent Market Forecast (2017-2027)
8.2.3.1. China Pneumococcal Vaccine Polyvalent Market Forecast (2017-2027)
8.2.3.2. Japan Pneumococcal Vaccine Polyvalent Market Forecast (2017-2027)
8.2.3.3. Korea Pneumococcal Vaccine Polyvalent Market Forecast (2017-2027)
8.2.3.4. India Pneumococcal Vaccine Polyvalent Market Forecast (2017-2027)
8.2.3.5. Southeast Asia Pneumococcal Vaccine Polyvalent Market Forecast (2017-2027)
8.2.3.6. Rest of Asia-Pacific Pneumococcal Vaccine Polyvalent Market Forecast (2017-2027)
8.2.4. South America Pneumococcal Vaccine Polyvalent Market Forecast (2017-2027)
8.2.4.1. Brazil Pneumococcal Vaccine Polyvalent Market Forecast (2017-2027)
8.2.4.2. Argentina Pneumococcal Vaccine Polyvalent Market Forecast (2017-2027)
8.2.4.3. Columbia Pneumococcal Vaccine Polyvalent Market Forecast (2017-2027)
8.2.4.4. Rest of South America Pneumococcal Vaccine Polyvalent Market Forecast (2017-2027)
8.2.5. Middle East and Africa Pneumococcal Vaccine Polyvalent Market Forecast (2017-2027)
8.2.5.1. Saudi Arabia Pneumococcal Vaccine Polyvalent Market Forecast (2017-2027)
8.2.5.2. United Arab Emirates Pneumococcal Vaccine Polyvalent Market Forecast (2017-2027)
8.2.5.3. Egypt Pneumococcal Vaccine Polyvalent Market Forecast (2017-2027)
8.2.5.4. Nigeria Pneumococcal Vaccine Polyvalent Market Forecast (2017-2027)
8.2.5.5. South Africa Pneumococcal Vaccine Polyvalent Market Forecast (2017-2027)
8.2.5.6. Turkey Pneumococcal Vaccine Polyvalent Market Forecast (2017-2027)
8.2.5.7. Rest of Middle East and Africa Pneumococcal Vaccine Polyvalent Market Forecast (2017-2027)
8.3. Pneumococcal Vaccine Polyvalent Market Forecast by Type (2017-2027)
8.3.1. Pneumococcal Vaccine Polyvalent Forecast by Type (2017-2027)
8.3.2. Pneumococcal Vaccine Polyvalent Market Share Forecast by Type (2017-2027)
List of Tables
List of Tables and Figures:
Figure United States Pneumococcal Vaccine Polyvalent Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Pneumococcal Vaccine Polyvalent Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Pneumococcal Vaccine Polyvalent Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Pneumococcal Vaccine Polyvalent Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Pneumococcal Vaccine Polyvalent Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Pneumococcal Vaccine Polyvalent Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Pneumococcal Vaccine Polyvalent Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Pneumococcal Vaccine Polyvalent Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Pneumococcal Vaccine Polyvalent Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Pneumococcal Vaccine Polyvalent Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Pneumococcal Vaccine Polyvalent Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Pneumococcal Vaccine Polyvalent Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Pneumococcal Vaccine Polyvalent Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Pneumococcal Vaccine Polyvalent Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Pneumococcal Vaccine Polyvalent Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Pneumococcal Vaccine Polyvalent Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Pneumococcal Vaccine Polyvalent Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Pneumococcal Vaccine Polyvalent Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Pneumococcal Vaccine Polyvalent Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Pneumococcal Vaccine Polyvalent Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Pneumococcal Vaccine Polyvalent Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Pneumococcal Vaccine Polyvalent Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Pneumococcal Vaccine Polyvalent Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Pneumococcal Vaccine Polyvalent Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Pneumococcal Vaccine Polyvalent Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Pneumococcal Vaccine Polyvalent Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Pneumococcal Vaccine Polyvalent Revenue and Revenue Share by Type (2017-2018)
Figure Global Prevnar 13 Revenue and Growth Rate (2017-2018)
Figure Global Pneumovax23 Revenue and Growth Rate (2017-2018)
Table Global Pneumococcal Vaccine Polyvalent Revenue by Regions (2017-2018)
Figure North America Pneumococcal Vaccine Polyvalent Growth Rate (2017-2018)
Figure North America Pneumococcal Vaccine Polyvalent Revenue and Growth Rate (2017-2018)
Figure North America Pneumococcal Vaccine Polyvalent by Countries (2017-2018)
Figure North America Pneumococcal Vaccine Polyvalent Revenue (Million USD) by Countries (2017-2018)
Figure United States Pneumococcal Vaccine Polyvalent Growth Rate (2017-2018)
Figure United States Pneumococcal Vaccine Polyvalent Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Pneumococcal Vaccine Polyvalent Growth Rate (2017-2018)
Figure Canada Pneumococcal Vaccine Polyvalent Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Pneumococcal Vaccine Polyvalent Growth Rate (2017-2018)
Figure Mexico Pneumococcal Vaccine Polyvalent Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Pneumococcal Vaccine Polyvalent Growth Rate (2017-2018)
Figure Europe Pneumococcal Vaccine Polyvalent Revenue and Growth Rate (2017-2018)
Figure Europe Pneumococcal Vaccine Polyvalent by Countries (2017-2018)
Figure Europe Pneumococcal Vaccine Polyvalent Revenue (Million USD) by Countries (2017-2018)
Figure Germany Pneumococcal Vaccine Polyvalent Growth Rate (2017-2018)
Figure Germany Pneumococcal Vaccine Polyvalent Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Pneumococcal Vaccine Polyvalent Growth Rate (2017-2018)
Figure France Pneumococcal Vaccine Polyvalent Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Pneumococcal Vaccine Polyvalent Growth Rate (2017-2018)
Figure UK Pneumococcal Vaccine Polyvalent Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Pneumococcal Vaccine Polyvalent Growth Rate (2017-2018)
Figure Russia Pneumococcal Vaccine Polyvalent Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Pneumococcal Vaccine Polyvalent Growth Rate (2017-2018)
Figure Italy Pneumococcal Vaccine Polyvalent Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Pneumococcal Vaccine Polyvalent Growth Rate (2017-2018)
Figure Rest of Europe Pneumococcal Vaccine Polyvalent Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Pneumococcal Vaccine Polyvalent Growth Rate (2017-2018)
Figure Asia-Pacific Pneumococcal Vaccine Polyvalent Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Pneumococcal Vaccine Polyvalent by Countries (2017-2018)
Figure Asia-Pacific Pneumococcal Vaccine Polyvalent Revenue (Million USD) by Countries (2017-2018)
Figure China Pneumococcal Vaccine Polyvalent Growth Rate (2017-2018)
Figure China Pneumococcal Vaccine Polyvalent Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Pneumococcal Vaccine Polyvalent Growth Rate (2017-2018)
Figure Japan Pneumococcal Vaccine Polyvalent Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Pneumococcal Vaccine Polyvalent Growth Rate (2017-2018)
Figure Korea Pneumococcal Vaccine Polyvalent Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Pneumococcal Vaccine Polyvalent Growth Rate (2017-2018)
Figure India Pneumococcal Vaccine Polyvalent Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Pneumococcal Vaccine Polyvalent Growth Rate (2017-2018)
Figure Southeast Asia Pneumococcal Vaccine Polyvalent Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Pneumococcal Vaccine Polyvalent Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Pneumococcal Vaccine Polyvalent Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Pneumococcal Vaccine Polyvalent Growth Rate (2017-2018)
Figure South America Pneumococcal Vaccine Polyvalent Revenue and Growth Rate (2017-2018)
Figure South America Pneumococcal Vaccine Polyvalent by Countries (2017-2018)
Figure South America Pneumococcal Vaccine Polyvalent Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Pneumococcal Vaccine Polyvalent Growth Rate (2017-2018)
Figure Brazil Pneumococcal Vaccine Polyvalent Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Pneumococcal Vaccine Polyvalent Growth Rate (2017-2018)
Figure Argentina Pneumococcal Vaccine Polyvalent Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Pneumococcal Vaccine Polyvalent Growth Rate (2017-2018)
Figure Columbia Pneumococcal Vaccine Polyvalent Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Pneumococcal Vaccine Polyvalent Growth Rate (2017-2018)
Figure Rest of South America Pneumococcal Vaccine Polyvalent Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Pneumococcal Vaccine Polyvalent Growth Rate (2017-2018)
Figure Middle East and Africa Pneumococcal Vaccine Polyvalent Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Pneumococcal Vaccine Polyvalent by Countries (2017-2018)
Figure Middle East and Africa Pneumococcal Vaccine Polyvalent Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Pneumococcal Vaccine Polyvalent Growth Rate (2017-2018)
Figure Saudi Arabia Pneumococcal Vaccine Polyvalent Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Pneumococcal Vaccine Polyvalent Growth Rate (2017-2018)
Figure United Arab Emirates Pneumococcal Vaccine Polyvalent Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Pneumococcal Vaccine Polyvalent Growth Rate (2017-2018)
Figure Egypt Pneumococcal Vaccine Polyvalent Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Pneumococcal Vaccine Polyvalent Growth Rate (2017-2018)
Figure Nigeria Pneumococcal Vaccine Polyvalent Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Pneumococcal Vaccine Polyvalent Growth Rate (2017-2018)
Figure South Africa Pneumococcal Vaccine Polyvalent Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Pneumococcal Vaccine Polyvalent Growth Rate (2017-2018)
Figure Turkey Pneumococcal Vaccine Polyvalent Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Pneumococcal Vaccine Polyvalent Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Pneumococcal Vaccine Polyvalent Revenue (Millions USD) and Growth Rate (2017-2018)
Table Merck & Co. Pneumococcal Vaccine Polyvalent Financial Overview
Table Pfizer Pneumococcal Vaccine Polyvalent Financial Overview
Figure Global Pneumococcal Vaccine Polyvalent Revenue (Millions USD) and Growth Rate (2018-2025)
Table Pneumococcal Vaccine Polyvalent Market Forecast by Regions (2018-2025)
Figure North America Pneumococcal Vaccine Polyvalent Market Forecast (2018-2025)
Figure United States Pneumococcal Vaccine Polyvalent Market Forecast (2018-2025)
Figure Canada Pneumococcal Vaccine Polyvalent Market Forecast (2018-2025)
Figure Mexico Pneumococcal Vaccine Polyvalent Market Forecast (2018-2025)
Figure Europe Pneumococcal Vaccine Polyvalent Market Forecast (2018-2025)
Figure Germany Pneumococcal Vaccine Polyvalent Market Forecast (2018-2025)
Figure France Pneumococcal Vaccine Polyvalent Market Forecast (2018-2025)
Figure UK Pneumococcal Vaccine Polyvalent Market Forecast (2018-2025)
Figure Russia Pneumococcal Vaccine Polyvalent Market Forecast (2018-2025)
Figure Italy Pneumococcal Vaccine Polyvalent Market Forecast (2018-2025)
Figure Rest of Europe Pneumococcal Vaccine Polyvalent Market Forecast (2018-2025)
Figure Asia-Pacific Pneumococcal Vaccine Polyvalent Market Forecast (2018-2025)
Figure China Pneumococcal Vaccine Polyvalent Market Forecast (2018-2025)
Figure Japan Pneumococcal Vaccine Polyvalent Market Forecast (2018-2025)
Figure Korea Pneumococcal Vaccine Polyvalent Market Forecast (2018-2025)
Figure India Pneumococcal Vaccine Polyvalent Market Forecast (2018-2025)
Figure Southeast Asia Pneumococcal Vaccine Polyvalent Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Pneumococcal Vaccine Polyvalent Market Forecast (2018-2025)
Figure South America Pneumococcal Vaccine Polyvalent Market Forecast (2018-2025)
Figure Brazil Pneumococcal Vaccine Polyvalent Market Forecast (2018-2025)
Figure Argentina Pneumococcal Vaccine Polyvalent Market Forecast (2018-2025)
Figure Columbia Pneumococcal Vaccine Polyvalent Market Forecast (2018-2025)
Figure Rest of South America Pneumococcal Vaccine Polyvalent Market Forecast (2018-2025)
Figure Middle East and Africa Pneumococcal Vaccine Polyvalent Market Forecast (2018-2025)
Figure Saudi Arabia Pneumococcal Vaccine Polyvalent Market Forecast (2018-2025)
Figure United Arab Emirates Pneumococcal Vaccine Polyvalent Market Forecast (2018-2025)
Figure Egypt Pneumococcal Vaccine Polyvalent Market Forecast (2018-2025)
Figure Nigeria Pneumococcal Vaccine Polyvalent Market Forecast (2018-2025)
Figure South Africa Pneumococcal Vaccine Polyvalent Market Forecast (2018-2025)
Figure Turkey Pneumococcal Vaccine Polyvalent Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Pneumococcal Vaccine Polyvalent Market Forecast (2018-2025)
Figure Global Pneumococcal Vaccine Polyvalent Forecast by Type (2018-2025)
Figure Global Pneumococcal Vaccine Polyvalent Market Share Forecast by Type (2018-2025)
Figure Global Pneumococcal Vaccine Polyvalent Forecast by Type (2018-2025)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|